Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NL-201 |
Synonyms | |
Therapy Description |
NL-201 is an agonist of the IL-2 and IL-15 receptors, with enhanced affinity for the beta and gamma subunits, which may stimulate natural killer and effector T cells, leading to an antitumor response (PMID: 37956421). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NL-201 | NL201|NL 201 | NL-201 is an agonist of the IL-2 and IL-15 receptors, with enhanced affinity for the beta and gamma subunits, which may stimulate natural killer and effector T cells, leading to an antitumor response (PMID: 37956421). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04659629 | Phase I | NL-201 | NL-201 in Patients With Relapsed or Refractory Cancer | Completed | USA | CAN | AUS | 0 |